cancer

FDA Grants AppliedVR Breakthrough Designation for Virtual Reality Chronic Pain Treatment

  • by

What You Should Know: – FDA awards AppliedVR Breakthrough Device designation for treating treatment-resistant fibromyalgia and chronic intractable lower back pain – AppliedVR’s EaseVRx program helps patients learn self-management skills grounded in evidence-based cognitive-behavioral therapy (CBT) principles and other behavioral methods. AppliedVR, a pioneer advancing… Read More »FDA Grants AppliedVR Breakthrough Designation for Virtual Reality Chronic Pain Treatment

JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

  • by

What You Should Know: – The U.S. government’s Joint Pathology Center, which houses the world’s largest human tissue repository, today announced that Proscia, a leading digital and AI pathology company, will provide end-to-end modernization of JPC’s pathology operations. – The multi-phase project will digitize the… Read More »JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

AstraZeneca’s Tagrisso (osimertinib) Receives the US FDA’s Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

  • by

Shots: AstraZeneca’s Tagrisso has received sNDA’s acceptance and has been granted PR in the US for the adjuvant treatment of patients with early-stage (IB, II, and IIIA) EGFRm NSCLC after complete tumor resection with curative intent The sNDA is based on the P-III ADAURA trial… Read More »AstraZeneca’s Tagrisso (osimertinib) Receives the US FDA’s Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

Fujifilm & Volpara Partner to Help Clinicians Determine Patient Breast Density

  • by

What You Should Know: – FUJIFILM Medical Systems U.S.A., Inc. and Volpara Solutions announced the extension of their partnership to provide mammography facilities and clinicians with breast imaging solutions designed to improve image quality, streamline workflow and accurately assess a patient’s breast density. – Building… Read More »Fujifilm & Volpara Partner to Help Clinicians Determine Patient Breast Density

AWS, PHDA Collaborate to Develop Breast Cancer Screening and Depression Machine Learning Models

  • by

What You Should Know: – Amazon Web Services (AWS) and the Pittsburgh Health Data Alliance (PHDA) announce a collaboration to produce more accurate machine learning models for breast cancer screening and depression. – In work funded through the PHDA-AWS collaboration, a research team led by… Read More »AWS, PHDA Collaborate to Develop Breast Cancer Screening and Depression Machine Learning Models

Shock as FDA rejects Mesoblast’s Ryoncil in paediatric graft versus host disease

  • by

The FDA has rejected Mesoblast’s Ryoncil cell therapy for children with graft versus host disease, despite a recommendation to approve from a panel of expert advisers. In August the FDA’s Oncology Drugs Advisory Committee voted nine to one in favour of approving Ryoncil (remestemcel-L), making… Read More »Shock as FDA rejects Mesoblast’s Ryoncil in paediatric graft versus host disease

Katie Porter lambasts big pharma over cancer drug price hike using whiteboard calculations – video

  • by

US representative Katie Porter used her now-signature whiteboard as she questioned former Celgene CEO Mark Alles over the connection between the significant price hike for Revlimid, a common cancer drug, and his personal bonus. The Democratic congresswoman for California presented her argument during a House oversight and… Read More »Katie Porter lambasts big pharma over cancer drug price hike using whiteboard calculations – video

TIGIT Therapies Digital Summit

  • by

The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT’s diverse function in multiple cell types has made it a lucrative immunotherapy candidate, with an increasing number of candidates being investigated in pre-clinical and clinical… Read More »TIGIT Therapies Digital Summit

NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy

  • by

NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning a previous rejection. The new guidance recommends Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine, for adults with diffuse large B-cell lymphoma (DLBCL), in second line… Read More »NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy

FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer

  • by

What You Should Know: The FDA and Syapse announce research collaboration expansion to address urgent public health challenges including supporting FDA’s goal of rapid understanding of COVID-19. As part of the research, Syapse is partnering with FDA’s Oncology Center of Excellence to investigate methods to… Read More »FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer

GSK nabs FDA approval for first-in-class multiple myeloma drug

  • by

Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies.

Armpit Shaving and Breast Cancer

  • by

Shaving before applying underarm antiperspirants can increase aluminum absorption. Could this explain the greater number of tumors and the disproportionate incidence of breast cancer in the upper outer quadrant of the breast near the armpit? A famous case report called “The Mortician’s Mystery,” published in… Read More »Armpit Shaving and Breast Cancer

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

  • by

Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of… Read More »Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

Bacteria and Colon Cancer

  • by

Let’s catch on some non-coronavirus research today with an interesting approach against a very bad disease, metastatic colon cancer. This new paper (from groups at Virginia Tech and Wake Forest) adds to our understanding of something that’s been noticed for some time: colon cancer tissue… Read More »Bacteria and Colon Cancer

Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases

  • by

Shots: The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts Quantro will exploit its functional-genetic… Read More »Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases

Virtually or In-Person, Automation Improves The Healthcare Experience

  • by

Muthu Alagappan, MD, Medical Director at Notable Health The COVID-19 pandemic has caused an unprecedented shift in the way consumers view and access a variety of goods and services—and healthcare is no exception. Recent studies show that many patients, including vulnerable populations like those living with cancer, are delaying recommended care and… Read More »Virtually or In-Person, Automation Improves The Healthcare Experience

Merck KGaA takes second option from cancer immunotherapy pact with F-Star

  • by

Germany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics.  The companies signed a deal to develop cancer immunotherapies in summer 2017, where Darmstadt-based Merck KGaA paid $115 million up front, agreeing to further payments during the first two years of… Read More »Merck KGaA takes second option from cancer immunotherapy pact with F-Star

NICE backs NHS use for Astellas’ Xospata after rethink

  • by

NICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia.  In final draft guidance NICE said that the drug is recommended for relapse or refractory FLT3 mutation-positive AML, giving patients an alternative to chemotherapy and its unpleasant side effects.  However because of… Read More »NICE backs NHS use for Astellas’ Xospata after rethink

Pelvic mesh scandal is what happens when men with power ignore women | Richard Vize

  • by

Cumberlege report is a damning reminder of how arrogant, intimidating doctors have suppressed their patients’ views Julia Cumberlege’s report into avoidable harm inflicted by the healthcare system exposes an institutional inability to listen to patients in general and women in particular. Her investigation into decades… Read More »Pelvic mesh scandal is what happens when men with power ignore women | Richard Vize

Philips and BioIntelliSense Integrate to Enhance Remote Patient Monitoring

What You Should Know: – Philips integrates the BioIntelliSense FDA-cleared BioSticker™ sensor as part of its remote patient monitoring solutions for patients outside the hospital. – Multi-parameter sensors aid monitoring across multiple chronic conditions with medical-grade vital signs for physicians to remotely track core symptoms,… Read More »Philips and BioIntelliSense Integrate to Enhance Remote Patient Monitoring

Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications

  • by

Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5… Read More »Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications

Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic

  • by

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we… Read More »Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic

Chia Seeds vs. Flaxseeds

  • by

  What effect do chia seeds have on weight loss, blood sugar, cholesterol, blood pressure, and inflammation? We’ve been eating chia seeds for more than 5,000 years. Historically, they are one of the main crops grown in the Western hemisphere. They are exceptionally high in… Read More »Chia Seeds vs. Flaxseeds

Medical Meat Bias

When famed surgeon Michael DeBakey was asked why his studies published back in the 1930s linking smoking and lung cancer were ignored, he had to remind people about what it was like back then. We were a smoking society. Smoking was in the movies, on… Read More »Medical Meat Bias

Does Aspartame Cause Lymphoma?

The approval of aspartame has a controversial history. The Commissioner of the U.S. Food and Drug Administration (FDA) concluded that “there is a reasonable certainty that human consumption of aspartame: (1) …will not pose a risk of brain damage resulting in mental retardation, endocrine [hormonal]… Read More »Does Aspartame Cause Lymphoma?

What About the Sodium in Miso?

  • by

According to the second World Cancer Research Fund/American Institute for Cancer Research expert report, “[s]alt is a probable cause of stomach cancer,” one of the world’s leading cancer killers. If the report’s estimate of an 8 percent increase in risk for every extra gram of… Read More »What About the Sodium in Miso?